Ctontinuous cefazolin infusion to treat bone and joint infections: Clinical efficacy, feasibility, safety, and serum and bone concentrations

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 883-887

  Zeller, Valérie ^a,c   Durand, Frédérick ^a   Kitzis, Marie Dominique ^b   Lhotellier, Luc ^a   Ziza, Jean Marc ^a   Mamoudy, Patrick ^a   Desplaces, Nicole ^a  

^a GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^b Hôpital Paris Saint Joseph   (France)

^c Hospital of Diaconesses Croix Saint Simon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; BONE INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; CONFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFECTIOUS ARTHRITIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AMBULATORY CARE; BLOOD; COHORT ANALYSIS; DRUG ADMINISTRATION; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; RETROSPECTIVE STUDY; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; CEFAZOLIN; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62949191132     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00389-08     Document Type: Article

References (31)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44: 79-86.
2. Barberan, J. 2006. Management of infections of osteoarticular prosthesis. Clin. Microbiol. Infect. 12:93-101.
3. Bernard, L, L El-Hajj, B. Pron, A. Lotthé, V. Gleizes, F. Signoret, P. Denormandie, J. L. Gaillard, and C. Perrone. 2001. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J. Clin. Pharm. Ther. 26:445-451.
4. Cancer Therapy Evaluation Program. 31 March 2003. Common terminology criteria for adverse events, version 3. DCTD. NCI, N1H, DHHS, Bethesda, MD. http://ctep.cancer.gov.
5. Connors, J. E., J. T. Dipiro, R. G. Hayter, K. D. Hooker, J. A. Stanfield, and T. R. Young. 1990. Assessment of cefazolin and cefuroxime tissue penetration by using a continuous infusion. Antimicrob. Agents Chemother. 34: 1128-1131.
6. Craig, W. A., and S. C. Ebert. 1992. Continuous infusion of [3-lactam antibiotics. Antimicrob. Agents Chemother. 36:2577-2583.
7. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
8. Cunha, B. A., H. R. Gossling, H. S. Pasternak, C. H. Nightingale, and R. Quintiliani. 1977. The penetration characteristics of cefazolin. cephalothin, and cephradine into bone in patients undergoing total hip replacement. J. Bone Joint Surg. Am. 59A:856-859.
9. Cunha, B. A., H. R. Gossling, H. S. Pasternak, C. H. Nightingale, and R. Quintiliani. 1984. Penetration of cephalosporins into bone. Infection 12:80-84.
10. Dellamonica, P., E. Bernard, H. Etesse, and R. Garraffo, 1986. The diffusion of pefloxacin into bone and the treatment of osteomyelitis. J. Antimicrob. Chemother. 17:93-102.
11. Desplaces, N., P. Mamoudy, F. Ducroquet, P. Larrouturou, and M. D. Kitzis. 1997. Vancomycine en perfusion continue et infections ostéo-articulairesa staphylocoques multiresistants. Med. Mal. Infect. 27:969-974.
12. Dripps, R. D., A. Lamont, and J, E. Eckenhoff. 1961. The role of anaesthesia in surgical mortality. JAMA 178:261-266.
13. Fass, R. 1978. Treatment of osteomyelitis and septic arthritis with cefazolin. Antimicrob. Agents Chemother. 13:405-411.
14. Fitzgerald, R. H. 1984. Antibiotic distribution in normal and osteomyelitic bone. Orthop. Clin. N. Am. 15:537-546.
15. Howard, G. W., E. J. Begg., S. T. Chambers, J, V, Brincat, M, Zhang, and C. M. Kirkpatrick. 2002. Free and total cefazolin plasma and interstitial fluid concentrations at steady state during continuous infusion. J. Antimicrob. Chemother. 50:429-432.
16. Karchmer, A. W. 2000. Cephalosporins, p. 274-291. In: G. L. Mandell. J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, PA.
17. Kasiakou, S. K., G. J. Sermaides, A. Michalopoulos, E. S. Soteriades, and M. E. Falagas. 2005. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect. Dis. 5:581-589.
18. Klassen, M., and S. C. Edberg. 1996. Measurement of antibiotics in human body fluids: techniques and significance, p. 230-295. In Antibiotics in laboratory medicine. 4th ed. The Williams & Wilkins Co., Baltimore. MD.
19. Kolzcun, M., C. L. Nelson, M. C. McHenry, T. L. Gavan, and P. Pinovich. 1974. Antibiotic concentrations in human bone. J. Bone Joint Surg. Am. 56A:305-310.
20. Lazzarini, L., B. A. Lipsky, and J. T. Mader. 2005. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int. J. Infect. Dis. 9:127-138.
21. Lew, D. P., and F. A. Waldvogel. 2004. Osteomyelitis. Lancet 364:369-379.
22. Mouton, J. W., U. Theuretzbacher, W. A. Craig, P. M. Tulkens, H. Derensdorf, and O. Cars. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
23. Reeves, D. S., R. Wise, J. M. Andrews, and L. O. White. 1999. Clinical antimicrobial assays. Oxford University Press Inc., New York. NY.
24. Sendi, P., M. Rohrbach, P. Graber, R. Frei, P. E. Ochsner, and W. Zimmerli. 2006. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin. Infect. Dis. 43:961-967.
25. Stengel, D., K. Bauwens, J. Sehouli, A. Ekkernkamp, and F, Porzsolt. 2001. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect. Dis. 1:175-188.
26. Thys, J. P., B. Vanderkelen, and J. Klastersky. 1976. Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans. Antimicrob. Agents Chemother. 10:395-398.
27. Tice, A. D., S. J. Rehm, J. R. Dalovisio, J. S. Bradley, L. P. Martinelli, D. R. Graham, R. B. Gainer, M. J. Kunkel, R. W. Yancey, and D. N. Williams. 2004. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin. Infect. Dis. 38:1651-1672.
28. Waltrip, T., R. Lewis, V. Young, M. Farmer, S. Clayton, S. Myers, L. A. Gray, and S. Galandiuk. 2002. A pilot study to determine the feasibility of continuous cefazolin infusion. Surg. Infect. 3:5-9.
29. Weinstein, M. P., C. W. Stratton, H. B. Hawley, A. Ackley, and L. B. Reller. 1987. Multicenter collaborative evaluation of standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am. J. Med. 83:218-222.
30. Wichmann, A., P. Lattke, A. Hartmann, W. Jaross, and K. J. Schulze. 2002. Bestimmung von Levofloxacin-Spiegeln im humanen Knochengewebe. Krankenhauspharmazie 23:207-212.
31. Zeller, V., and N. Desplaces. 2006. Antibiothérapie des infections ostéoarticulairesà pyogènes chez I'adulte: principes et modalités. Rev. Rhum. 73:129-135.